Analyst David Martin PhD of Bloom Burton maintained a Buy rating on Medicenna Therapeutics Corp, retaining the price target of $6.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
David Martin PhD’s rating is based on the growing interest in PD-1 bispecific antibodies within the pharmaceutical industry, as evidenced by recent high-value deals. Medicenna Therapeutics Corp is well-positioned in this promising field, which has seen significant investments from major players like Merck, Pfizer, and Takeda.
The strategic partnerships and substantial upfront payments in the sector highlight the potential value and demand for innovative oncology treatments. This context suggests that Medicenna’s focus on PD-1/IL-2 bispecifics could lead to lucrative opportunities, justifying the Buy rating.
Martin PhD covers the Healthcare sector, focusing on stocks such as Aurinia Pharmaceuticals, Medicenna Therapeutics Corp, and HLS Therapeutics Inc. According to TipRanks, Martin PhD has an average return of 17.3% and a 48.44% success rate on recommended stocks.
In another report released on October 14, Lucid Capital also initiated coverage with a Buy rating on the stock with a C$4.00 price target.